N-(3-Morpholinopropyl) Gefitinib

• CAT Number: C000724
• CAS Number: 1502829-45-9
• Molecular Formula: C₂₉H₃₇ClFN₅O₄
• Molecular Weight: 574.09
• Purity: ≥95%
• Synonyms: N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-N-[3-(4-morpholinyl)propyl]-4-quinazolinamine
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• Appearance: Light Yellow to Yellow Solid
• Storage: -20°C, Inert atmosphere
• IUPAC Name: N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)-N-(3-morpholin-4-ylpropyl)quinazolin-4-amine
• InChI: InChI=1S/C29H37ClFN5O4/c1-37-27-20-26-23(19-28(27)40-13-3-7-35-11-16-39-17-12-35)29(33-21-32-26)36(22-4-5-25(31)24(30)18-22)8-2-6-34-9-14-38-15-10-34/h4-5,18-21H,2-3,6-17H2,1H3
• InChIKey: MCDVSKSUNKYMRM-UHFFFAOYSA-N
• SMILES: COC1=C(C=C2C(=C1)N=CN=C2N(CCCN3CCOCC3)C4=CC(=C(C=C4)F)Cl)OCCCN5CCOCC5

N-(3-Morpholinopropyl) Gefitinib (Cat No.:C000724) is a derivative of gefitinib, a targeted therapy medication used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC). This compound involves the addition of a 3-morpholinopropyl group to gefitinib. The modification may impact the drug’s pharmacological properties, potentially influencing its interactions with cancer cells and targeted pathways. Research on N-(3-Morpholinopropyl) Gefitinib likely explores its efficacy, bioavailability, and mechanism of action, aiming to optimize its therapeutic potential and broaden its application in cancer treatment regimens.

Reference

Anderson, N.G., et al.: Int. J. Cancer, 94, 774 (2001); Hirata, A., et al.: Cancer Res., 62, 2554 (2002); Kris, M.G., et al.: J. Am. Med. Assoc., 290, 2149 (2003); Tamura, K., et al.: Expert Opin. Pharmacother., 6, 985 (2005); Ranson, M., et al.: J. Clin. Oncology, 20, 2240 (2002); Mendelsohn, J., et al.: J. Clin. Oncology, 21, 2787 (2003); McKillop, D., et al.: Xenobiotica, 10, 917 (2004);